Evidence map›Paper›PMID 38228802›Full record

ArticleCell death and differentiation2024

ABLIM1, a novel ubiquitin E3 ligase, promotes growth and metastasis of colorectal cancer through targeting IĸBα ubiquitination and activating NF-ĸB signaling.

Ying He, Qian Shi, Yuhang Ling, Huihui Guo, Yi Fei, Ruoyu Wu, Chengwu Tang, Xilin Zhang, Linhua Yao

Open access · hybridAbstract read
In one paragraph

Article in Cell death and differentiation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. USP35 Acts as a Deubiquitinating Enzyme for ID3 to Promote Immune Escape in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. Article
  8. Glycolysis enzymes and cellular lactylation in tumour.Clinical and translational medicine · 2026
    Review
  9. Cancer Stem Cells Shift Metabolite Acetyl-Coenzyme A to Abrogate the Differentiation of CD103Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. To B or Not to B: Germinal Center Responses in Progressive Fibrotic Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ying He *Central Laboratory, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Qian Shi *Central Laboratory, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Yuhang LingCentral Laboratory, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Huihui GuoCentral Laboratory, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Yi FeiDepartment of Colorectal Surgery, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Ruoyu WuDepartment of Gastroenterology, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Chengwu TangCentral Laboratory, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China. tamgche@sina.com.
Xilin ZhangCentral Laboratory, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China. 51378@zjhu.edu.cn.
Linhua YaoHuzhou Key Laboratory of Translational Medicine, First People's Hospital of Huzhou, Huzhou, 313000, Zhejiang, China. yaolinhua110@163.com.ORCID 0000-0003-3110-1608
Huzhou University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81970570National Natural Science Foundation of China (National Science Foundation of China) 82204519Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LGD20H030001
6 · The paper itself

Abstract

Actin-binding LIM protein 1 (ABLIM1), a member of the LIM-domain protein family, has been reported as a suppressor in several tumors whereas its role in colorectal cancer (CRC) remains unknown. In this study, we find that ABLIM1 is up-regulated in CRC patients and high levels of ABLIM1 predict short disease-free survival time. Knock-down of ABLIM1 in CRC cell lines by lenti-virus leads to inhibited cell proliferation, migration, and invasion capabilities in vitro and impaired growth of tumor xenografts and liver metastasis lesions in vivo, while ABLIM1 overexpression accelerates tumor growth and invasion in vitro. Mechanistically, we uncover that ABLIM1 activates the NF-ĸB/CCL-20 signaling through modulating IĸBα ubiquitination and proteasomal-mediated degradation. Further co-immunoprecipitation, in vivo and in vitro ubiquitination assays reveal ABLIM1 as a novel ubiquitin E3 ligase binding to IĸBα. Interestingly, The E3 ligase catalysis activity of ABLIM1 depends on its 402-778aa rather than its LIM domains and its interaction with IĸBα relies on the HP domain. Our findings delineate the oncogenic role of ABLIM1 in CRC progression and reveal it as a novel E3 ligase targeting IĸBα, providing new insights into the regulation of NF-ĸB signaling in tumors.

Indexed as

Colorectal NeoplasmsUbiquitin-Protein LigasesCell Line, TumorHumansLIM Domain ProteinsMicrofilament ProteinsNF-kappa BNF-KappaB Inhibitor alphaUbiquitinUbiquitinationABLIM1 protein, humanLIM Domain ProteinsMicrofilament ProteinsNF-kappa BNF-KappaB Inhibitor alphaNFKBIA protein, humanUbiquitinUbiquitin-Protein Ligases

Identifiers

PMID38228802
PMCPMC10850134
OpenAlexW4390904459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.